biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
Company profile
Ticker
BCRX
Exchange
Website
CEO
Jon Stonehouse
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
BioCryst Canada, ULC • BioCryst España S.L. • BioCryst France SAS • BioCryst Ireland Limited • BioCryst Italia S.r.l. • BioCryst Japan K.K. • BioCryst Netherlands B.V. • BioCryst Pharma Deutschland GmbH • BioCryst Schweiz GmbH • BioCryst UK Limited ...
IRS number
621413174
BCRX stock data
Latest filings (excl ownership)
S-3ASR
Automatic shelf registration
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
26 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
18 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Departure of Directors or Certain Officers
1 Dec 23
8-K
Regulation FD Disclosure
30 Nov 23
S-8
Registration of securities for employees
8 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Regulation FD Disclosure
3 Nov 23
Transcripts
BCRX
Earnings call transcript
2023 Q4
26 Feb 24
BCRX
Earnings call transcript
2023 Q3
2 Nov 23
BCRX
Earnings call transcript
2023 Q2
3 Aug 23
BCRX
Earnings call transcript
2023 Q1
3 May 23
BCRX
Earnings call transcript
2022 Q4
21 Feb 23
BCRX
Earnings call transcript
2022 Q3
1 Nov 22
BCRX
Earnings call transcript
2022 Q2
4 Aug 22
BCRX
Earnings call transcript
2022 Q1
5 May 22
BCRX
Earnings call transcript
2021 Q4
23 Feb 22
BCRX
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
Helen M. Thackray
2 Apr 24
4
VINCENT MILANO
4 Mar 24
4
THERESA HEGGIE
4 Mar 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G
Avoro Capital Advisors LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
24 Jan 24
SC 13G/A
STATE STREET CORP
24 Jan 24
4
Jon P Stonehouse
4 Jan 24
4
Helen M. Thackray
20 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 150.91 mm | 150.91 mm | 150.91 mm | 150.91 mm | 150.91 mm | 150.91 mm |
Cash burn (monthly) | (no burn) | 8.00 mm | 11.94 mm | 19.54 mm | 6.63 mm | 9.17 mm |
Cash used (since last report) | n/a | 54.79 mm | 81.77 mm | 133.86 mm | 45.42 mm | 62.82 mm |
Cash remaining | n/a | 96.12 mm | 69.13 mm | 17.05 mm | 105.48 mm | 88.08 mm |
Runway (months of cash) | n/a | 12.0 | 5.8 | 0.9 | 15.9 | 9.6 |
Institutional ownership, Q3 2023
84.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 230 |
Opened positions | 21 |
Closed positions | 24 |
Increased positions | 99 |
Reduced positions | 57 |
13F shares | Current |
---|---|
Total value | 1.24 tn |
Total shares | 175.03 mm |
Total puts | 297.10 k |
Total calls | 2.00 mm |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 16.77 mm | $118.76 bn |
Vanguard | 15.39 mm | $108.98 bn |
Baker Bros. Advisors | 12.71 mm | $89.99 bn |
Avoro Capital Advisors | 11.55 mm | $81.77 bn |
STT State Street | 10.47 mm | $74.10 bn |
Braidwell | 5.36 mm | $37.97 bn |
Millennium Management | 4.98 mm | $35.28 bn |
Pictet Asset Management Holding | 4.19 mm | $29.68 bn |
Geode Capital Management | 3.91 mm | $27.69 bn |
RP Management | 3.85 mm | $27.23 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 24 | Thackray Helen M. | Common Stock | Payment of exercise | Dispose F | No | No | 5.08 | 7,525 | 38.23 k | 242,139 |
29 Feb 24 | Theresa Heggie | Common Stock | Grant | Acquire A | No | No | 5.63 | 999 | 5.62 k | 51,860 |
29 Feb 24 | Milano Vincent | Common Stock | Grant | Acquire A | No | No | 5.63 | 999 | 5.62 k | 51,997 |
3 Jan 24 | Stonehouse Jon P | Common Stock | Gift | Acquire G | Yes | No | 0 | 10,000 | 0.00 | 20,000 |
3 Jan 24 | Stonehouse Jon P | Common Stock | Gift | Acquire G | Yes | No | 0 | 10,000 | 0.00 | 20,000 |
3 Jan 24 | Stonehouse Jon P | Common Stock | Gift | Dispose G | No | No | 0 | 20,000 | 0.00 | 1,094,770 |
19 Dec 23 | Alane P Barnes | Common Stock | Payment of exercise | Dispose F | No | No | 6.05 | 2,482 | 15.02 k | 293,539 |
News
Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target
10 Apr 24
What's Going On With BioCryst Stock After Earnings?
26 Feb 24
10 Health Care Stocks With Whale Alerts In Today's Session
26 Feb 24
BioCryst Pharma Q4 Adjusted EPS $(0.28) Misses $(0.24) Estimate, Sales $93.40M Beat $90.01M Estimate
26 Feb 24
Earnings Scheduled For February 26, 2024
26 Feb 24
Press releases
BioCryst to Report First Quarter 2024 Financial Results on May 6
22 Apr 24
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
17 Apr 24
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 Apr 24
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Mar 24
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
26 Feb 24